Perth-based burns treatment developer Clinical Cell Culture Ltd, or C3, has won approval for the sale of its ReCell tissue harvesting device in Brazil and Turkey, the company announced today.
The full text of a company announcement is pasted below
Clinical Cell Culture Ltd today announced that its ReCell tissue harvesting device has been approved for commercial sales in Brazil and Turkey.
ReCell is a unique medical device that assists plastic, cosmetic, dermatology and burn surgeons in repairing a wide range of skin defects including scar revision, hypo pigmentation and vitiligo. The product is also used in a number of cosmetic procedures including laser resurfacing and dermabrasion and is intended for use in patients with injuries of up to 2 per cent of the body surface or 320 sqcm.
C3 Chief Executive Officer Bob Atwill said he was delighted that regulatory approval had been received on schedule in these key markets.
"South America in particular is a key market and we have had a large number of enquiries following recent conferences in the region including the ISBI (International Society for Burn Injuries) held in Brazil in September," said Mr Atwill.
"Sales to our distributors in both Brazil and Turkey will commence this quarter."
ReCell is now approved for sale in over 40 countries worldwide, including Canada, Germany, Italy, United Kingdom, Australia and Japan.
